Xeruborbactam

Synonym(s): QPX-7728  |  ORAvance  |  OMNIvance

Class: Beta-lactamase inhibitor

Spectrum of activity:	Gram-negative
Details of activity:	Active against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii
Description:	To be paired with beta-lactams for ORAvance and OMNIvance
Institute where first reported:	Qpex Biopharma; Brii Biosciences
Year first mentioned:	2020
Highest developmental phase:	Phase 1 (NCT04380207)
Development status:	Active (as of 2024)

Chemical structure(s):
Canonical SMILES:	C1=C2[C@H]3C[C@H]3B(O)OC2=C(C(=C1)F)C(=O)O
Isomeric SMILES:	B1([C@@H]2C[C@@H]2C3=C(O1)C(=C(C=C3)F)C(=O)O)O
InChI:	InChI=1S/C10H8BFO4/c12-7-2-1-4-5-3-6(5)11(15)16-9(4)8(7)10(13)14/h1-2,5-6,15H,3H2,(H,13,14)/t5-,6-/m1/s1
InChI Key:	KOHUFVUIYUCFNG-PHDIDXHHSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/140830474

External links:
Guide to Pharmacology:	xeruborbactam
Main Source:	https://aac.asm.org/content/64/6/e00212-20
Citations:	https://aac.asm.org/content/64/6/e00130-20 https://aac.asm.org/content/early/2020/05/27/AAC.00757-20/article-info?versioned=true https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01976